BMO Capital Maintains Outperform on Bristol-Myers Squibb, Lowers Price Target to $79
Portfolio Pulse from richadhand@benzinga.com
BMO Capital analyst Evan Seigerman has maintained an 'Outperform' rating on Bristol-Myers Squibb (NYSE:BMY) but lowered the price target from $87 to $79.
July 28, 2023 | 2:03 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Bristol-Myers Squibb's price target has been lowered from $87 to $79 by BMO Capital, though the 'Outperform' rating is maintained.
The news directly pertains to Bristol-Myers Squibb as BMO Capital has lowered its price target for the company. However, the 'Outperform' rating is maintained, indicating that the analyst still expects the stock to do well. This could have a neutral impact on the stock's price in the short term as the lowered price target might be offset by the positive rating.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100